The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for POINT Biopharma Global Inc. (PNT) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $7.07. The POINT Biopharma Global Inc. has recorded 116,183 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted POINT Biopharma Completes Randomization in PNT2002’s Phase 3 SPLASH Trial.
POINT Biopharma Global Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $7.07 and fluctuated between $7.15 as its day high and $6.93 as its day low. The current market capitalization of POINT Biopharma Global Inc. is $764.69M. A total of 0.64 million shares were traded on the day, compared to an average of 772.68K shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, PNT has seen 8 BUY and 0 SELL insider trades, representing the acquisition of 70,830 and the disposition of 0 shares. Over the last 12 months, there were 8 BUYs and 1 SELLs from insiders. Insiders purchased 70,830 shares during that period but sold 564,204.
In the most recent transaction, MCCANN JOE A. bought 2,160 shares of PNT for 6.64 per share on Nov 29. After the transaction, the Chief Executive Officer now owns 3,616,313 company shares. In a previous transaction on Nov 28, Malik Rajesh bought 3,700 shares at 6.66 per share. PNT shares that Director owns now total 3,700.
Among the insiders who bought shares, HOGUE GERALD L. acquired of 3,660 shares on Nov 25 at a per-share price of $6.82. This resulted in the Director holding 3,660 shares of PNT after the transaction. In another insider transaction, Lubner David Charles bought 3,600 shares at $6.85 per share on Nov 23. Company shares held by the Director now total 3,600.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for PNT in the last 3 months, the mean price target is $16.50 with high estimates of $28.00 and low estimates of $10.00. In terms of 52-week highs and lows, PNT has a high of $10.98 and a low of $5.22.
As of this writing, PNT has an earnings estimate of -$0.28 per share for the current quarter. EPS was calculated based on a consensus of 9 estimates, with a high estimate of -$0.25 per share and a lower estimate of -$0.34. The company reported an EPS of -$0.18 in the last quarter, which was 14.30% higher than expectations of -$0.21.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 12 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PNT is Hold with a score of 4.91. A total of 11 analysts rated the stock as Buy while 1 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.